FY2024 EPS Estimates for Valneva Decreased by HC Wainwright

Valneva SE (NASDAQ:VALN) – Stock analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Valneva in a report issued on Thursday, January 23rd. HC Wainwright analyst E. White now anticipates that the company will post earnings of $0.13 per share for the year, down from their prior forecast of $0.15. HC Wainwright currently has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Valneva’s FY2025 earnings at ($1.29) EPS and FY2026 earnings at ($1.17) EPS.

Valneva Stock Up 3.4 %

Shares of VALN stock opened at $4.90 on Monday. The stock’s 50 day simple moving average is $4.29 and its 200 day simple moving average is $5.76. Valneva has a twelve month low of $3.62 and a twelve month high of $9.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The company has a market capitalization of $398.17 million, a price-to-earnings ratio of -37.69 and a beta of 1.93.

Institutional Trading of Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC boosted its holdings in Valneva SE (NASDAQ:VALN) by 33.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 as of its most recent SEC filing. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.